乳腺肿瘤生长抑素受体表达与生长抑素受体显像

目的 探讨生长抑素受体(SSTR)显像对乳腺癌的诊断价值。方法 15例乳腺癌患者术前进行99mTc-奥曲肽SSTR显像,勾画感兴趣区,计算瘤体与对侧正常组织的放射性比值(T/N),术后采用逆转录-聚合酶链反应检测肿瘤组织SSTR1-SSTR5 mRNA的表达,SP免疫组化法比较该15例乳腺癌和18例乳腺良性病变组织SSTR2和SSTR5的表达水平。结果 ①15例乳腺癌患者99mTc-奥曲肽SSTR显像均为阳性,T/N为1.873±0.341;②15例乳腺癌组织的SSTR1、SSTR2、SSTR3、SSTR4、SSTR5mRNA表达阳性率分别为100%(15/15)、93.30%(14/15)、100%(15/15)、46.70%(7/15)、86.70%(13/15),以甘油醛-3-磷酸脱氢酶(GAPDH)基因为内参基因计算的mRNA表达量,从高到低分别为SSTR3、SSTR1、SSTR2、SSTR5、SSTR4,SSTR2 mRNA表达水平与乳腺癌显像T/N呈正相关,有显著的统计学意义(r=0.728,P<0.01);③SP免疫组化结果显示,乳腺癌组织的SSTR2和SSTR5的表达明显高于乳腺良性病变组织。结论 乳腺癌组织有丰富的SSTR表达,明显高于乳腺良性病变组织,99mTc-奥曲肽SSTR显像对乳腺癌有较好的靶向诊断价值。

Somatostatin receptor scintigraphy and somatostatin receptors expression in breast neoplasm

Objective To evaluate the value of 99mTc-octreotide somatostatin receptor (SSTR) scintig-raphy in breast cancer.Methods 15 breast cancer patients underwent 99mTc-octreotide SSTR scintigraphy before surgery, and tumor to normal tissue ratio (T/N) was calculated. mRNA expression of SSTR 1, SSTR2, SSTR3, SSTR4, SSTR5 was detected by RT-PCR after surgery. And SSTR2 and SSTR5 expressions were detected by immunohistochemical staining in these 15 breast carcinoma as well as other 18 benign breast tissue.Results All of the 15 breast cancer patients showed intense uptake of 99mTc-octreotide, and T/N values were 1.873±0.341. All five SSTR sub-types were variably expressed at the mRNA level in breast cancer with 100% (15/15)amplesshowing SSTR1, 93.30% (14/15) SSTR2, 100% (15/15) SSTR3, 46.70% (7/15)SSTR4 and 86.70% (13/15)SSTR5. Levels of SSTR mRNA, when corrected for glyeraldehyde 3-phosphaate dehydrogenase gene levels, were highest for SSTR3 followed by SSTR1, SSTR2, SSTR5, and SSTR4. Good correlation was obtained between the ratio of T/N and the expression of SSTR2 mRNA (r=0.728, P<0.01). Both the expression of SSTR2 and SSTR5 are higher in malignant ones than in benign breast tissues.Conclusion The results indicate that there was high expression of SSTR in breast cancer. SSTR scintigraphy is of great value in targeted detection of breast cancer.